Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Barclays Downgrades SpringWorks Therapeutics to Equal-Weight, Lowers Price Target to $47

Author: Benzinga Newsdesk | April 28, 2025 12:28pm
Barclays analyst Peter Lawson downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Overweight to Equal-Weight and lowers the price target from $63 to $47.

Posted In: SWTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist